SlideShare ist ein Scribd-Unternehmen logo
1 von 2
Downloaden Sie, um offline zu lesen
Adjunctive steroids for reducing residual pleural effusion in patients
                                 with TB
CITATION
Fleishman SI, Coetzee AM, Mindel S, Berjak J, Lichter AI. Antituberculous therapy combined with
adrenal steroids in the treatment of pleural effusions: a controlled therapeutic trial. Lancet. 1960 Jan
23;1:199-201


RESEARCH QUESTION
Compared to standard therapy, how effective is adjunctive steroid therapy for treating patients with
pleural effusion of unknown cause?

THE STUDY
Controlled therapeutic trial.

STUDY SETTING
Central hospital within the mining area of Witwatersrand, Johannesburg.

PARTICIPANTS
Included:  Mineworkers with pleural effusion of unknown cause, presumably all men.
Excluded:  Patients with Pulmonary Tuberculosis (TB), other TB, adenopathy, abdominal
           masses, vitamin deficiency, bilateral effusions.


INTERVENTIONS
   1. Treatment V: Ascorbic Acid 500mg IM daily for 14 days
   2. Treatment P: Procaine Penicillin 300,000 units IM twice daily for 14 days
   3. Treatment T: ATT (see below)
   4. Treatment TS: ATT plus corticosteroids (see below)

                       Regular   ATT            ATT Plus
 Description   Streptomycin      INH            Prednisolone
 Dosage        1g IM             200mg orally   10mg orally, then 5 mg orally
 Frequency     Daily             3 times/d      3 times daily, then 3 times daily for rest of 8 weeks
 Duration      8 wks             8 weeks        for 2 days at higher dose, rest of 8 weeks at lower dose


Co-interventions:       1. 3 tablets Vit B co daily
                        2. Bedrest

OUTCOMES
Primary:   Reduction in the extent of pleural effusion
Secondary: Are scurvy and pneumonia involved in the pathogenesis of pleurisy?


RISK OF BIAS            (Risk Scale: Low – Moderate – High)

SELECTION BIAS: moderate to high
Previously prepared sealed instructions of treatment. As each case was admitted to the trial,
hospital clerical staff drew one so that the treatment was allocated at random. Table 1: Appears to
be balanced for Initial weights and Initial ESR. However no other parameters (e.g. demographics)
are reported on. The ESR appears to be low for TB for which you would normally expect readings
of around 40+ mm/hr.
PERFORMANCE BIAS: low
(ie: What else happened that may have affected the result?)
Patients not blinded - Not a problem since outcome is not affected by patient’s performance.
Patients were confined to hospital – good compliance to therapy
Period of bed rest varied according to “patient’s condition” – article did not clarify who made this
judgement.
Initial aspiration of 20 ml of pleural fluid may affect first four weeks’ score.


DETECTION BIAS: low
Pleural effusions were scored by a panel of 5 doctors who, according to the authors, were blinded
to the patient's treatment. No indication that the laboratory staff was blinded.

However, it appears as if the panel were aware of the treatment given at the beginning of the trial
since on page 200, column 2 – "this result became known only at the completion of his course of
treatment" almost indicating that they would have changed the treatment had they known?


ATTRITION BIAS:
No intention to treat analysis performed.


                                   P        V       ATT     ATT + S        Total
            Started                19       21       19       20            79
            Completed              17       19       19       20            75
            Assessed               16       18       19       20            73


STUDY FINDINGS
Significant reduction in the extent of the effusion in TS at 4 weeks
No significant reduction seen from 4 weeks to 8 weeks

PRESENCE OF RESIDUAL FLUID (95% CI)
          Treatment    Event Rate                     RRR                  ARR           NNT
  4 weeks    TS     E 11/20 = 0.55                     35%                 0.29           4
              T     C 16/19 = 0.84                  (2%; 67%)          (0.02; 0.57)    (2 – 52)

  8 weeks         TS        E     8/20 = 0.40         49%                  0.39            3
                   T        C    15/19 = 0.79      (14%; 85%)          (0.11; 0.67)     (1 – 9)



ADVERSE EVENTS
Four patients deteriorated: Treatment change from V, P to T, TS


COMMENTS
Adjunctive steroid therapy appears to be an effective treatment for reducing residual pleural fluid in
patients with pleural effusion of unknown cause.



Prepared by: MARK ENGEL
E-mail:      mark.engel@mrc.ac.za
Date:        15 June 2004

Weitere ähnliche Inhalte

Ähnlich wie Steroidsfleishman

Doppler Guided Intraoperative Fluid Management Data Analysis
Doppler Guided Intraoperative Fluid Management  Data AnalysisDoppler Guided Intraoperative Fluid Management  Data Analysis
Doppler Guided Intraoperative Fluid Management Data Analysisfast.track
 
Clinical inertia short
Clinical inertia shortClinical inertia short
Clinical inertia shortIhsaan Peer
 
Acute Chest Syndrome of Sickle Cell Anemia
Acute Chest Syndrome of Sickle Cell AnemiaAcute Chest Syndrome of Sickle Cell Anemia
Acute Chest Syndrome of Sickle Cell AnemiaAhmed AlGahtani, RRT
 
Uveitis: Workup and Management
Uveitis: Workup and ManagementUveitis: Workup and Management
Uveitis: Workup and ManagementSmith Snehal Sute
 
201911 - Solidoro - Ambiti di utilizzo della “triplice”
201911 - Solidoro - Ambiti di utilizzo della “triplice”201911 - Solidoro - Ambiti di utilizzo della “triplice”
201911 - Solidoro - Ambiti di utilizzo della “triplice”Asmallergie
 
Mucinous cystadenoma case presentation
Mucinous cystadenoma case presentationMucinous cystadenoma case presentation
Mucinous cystadenoma case presentationShadmanAbdalJoarder
 
杜斌:如何做一名ICU医生
杜斌:如何做一名ICU医生杜斌:如何做一名ICU医生
杜斌:如何做一名ICU医生neuroccm
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
 
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017Melbourne Bioanalytics
 
Thrombo emmolic compilications in nicu
Thrombo emmolic compilications in nicuThrombo emmolic compilications in nicu
Thrombo emmolic compilications in nicuOsama Elfiki
 
中醫泌尿道保健檔案.pdf
中醫泌尿道保健檔案.pdf中醫泌尿道保健檔案.pdf
中醫泌尿道保健檔案.pdfJennyKuo17
 
Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Jon Sweet
 
Case Presentation in SOAP Format
Case Presentation in SOAP FormatCase Presentation in SOAP Format
Case Presentation in SOAP FormatAbel C. Mathew
 

Ähnlich wie Steroidsfleishman (20)

Doppler Guided Intraoperative Fluid Management Data Analysis
Doppler Guided Intraoperative Fluid Management  Data AnalysisDoppler Guided Intraoperative Fluid Management  Data Analysis
Doppler Guided Intraoperative Fluid Management Data Analysis
 
Clinical inertia short
Clinical inertia shortClinical inertia short
Clinical inertia short
 
Sepsis guidlines
Sepsis guidlinesSepsis guidlines
Sepsis guidlines
 
Acute Chest Syndrome of Sickle Cell Anemia
Acute Chest Syndrome of Sickle Cell AnemiaAcute Chest Syndrome of Sickle Cell Anemia
Acute Chest Syndrome of Sickle Cell Anemia
 
Uveitis: Workup and Management
Uveitis: Workup and ManagementUveitis: Workup and Management
Uveitis: Workup and Management
 
201911 - Solidoro - Ambiti di utilizzo della “triplice”
201911 - Solidoro - Ambiti di utilizzo della “triplice”201911 - Solidoro - Ambiti di utilizzo della “triplice”
201911 - Solidoro - Ambiti di utilizzo della “triplice”
 
FARM ANALYSIS - Pharm. D.pptx
FARM ANALYSIS - Pharm. D.pptxFARM ANALYSIS - Pharm. D.pptx
FARM ANALYSIS - Pharm. D.pptx
 
Mucinous cystadenoma case presentation
Mucinous cystadenoma case presentationMucinous cystadenoma case presentation
Mucinous cystadenoma case presentation
 
杜斌:如何做一名ICU医生
杜斌:如何做一名ICU医生杜斌:如何做一名ICU医生
杜斌:如何做一名ICU医生
 
Austin Immunology
Austin ImmunologyAustin Immunology
Austin Immunology
 
Austin Internal Medicine
Austin Internal MedicineAustin Internal Medicine
Austin Internal Medicine
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
 
Radiotherapy in Seminoma
Radiotherapy in SeminomaRadiotherapy in Seminoma
Radiotherapy in Seminoma
 
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017
"An Omics Investigation of Widespread Pain" by Dr Neil McGregor, 2017
 
Thrombo emmolic compilications in nicu
Thrombo emmolic compilications in nicuThrombo emmolic compilications in nicu
Thrombo emmolic compilications in nicu
 
Case discussion
Case discussionCase discussion
Case discussion
 
中醫泌尿道保健檔案.pdf
中醫泌尿道保健檔案.pdf中醫泌尿道保健檔案.pdf
中醫泌尿道保健檔案.pdf
 
Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015
 
2011 Annual Shareholder Meeting Presentation
2011 Annual Shareholder Meeting Presentation2011 Annual Shareholder Meeting Presentation
2011 Annual Shareholder Meeting Presentation
 
Case Presentation in SOAP Format
Case Presentation in SOAP FormatCase Presentation in SOAP Format
Case Presentation in SOAP Format
 

Mehr von Dr Amolkumar W Diwan

Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Dr Amolkumar W Diwan
 
Naco guidelines for hiv aids management
Naco guidelines for hiv aids managementNaco guidelines for hiv aids management
Naco guidelines for hiv aids managementDr Amolkumar W Diwan
 
Traction bronchiectasis bronchiectasis notes
Traction bronchiectasis bronchiectasis notesTraction bronchiectasis bronchiectasis notes
Traction bronchiectasis bronchiectasis notesDr Amolkumar W Diwan
 
Pleural thickening 2009 janvol7issue1
Pleural thickening 2009 janvol7issue1Pleural thickening 2009 janvol7issue1
Pleural thickening 2009 janvol7issue1Dr Amolkumar W Diwan
 
Naco guidelines for hiv aids management
Naco guidelines for hiv aids managementNaco guidelines for hiv aids management
Naco guidelines for hiv aids managementDr Amolkumar W Diwan
 
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Dr Amolkumar W Diwan
 

Mehr von Dr Amolkumar W Diwan (20)

Diabetes mellitus amol
Diabetes mellitus amolDiabetes mellitus amol
Diabetes mellitus amol
 
Incremental shuttle walking test
Incremental shuttle walking testIncremental shuttle walking test
Incremental shuttle walking test
 
Pulmonary rehab clinic protocol
Pulmonary rehab clinic protocolPulmonary rehab clinic protocol
Pulmonary rehab clinic protocol
 
Copd cipladoc
Copd cipladocCopd cipladoc
Copd cipladoc
 
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
 
Anatomic variation
Anatomic variationAnatomic variation
Anatomic variation
 
Chest and tuberculosis
Chest and tuberculosisChest and tuberculosis
Chest and tuberculosis
 
Md & ms curriculum
Md &  ms curriculumMd &  ms curriculum
Md & ms curriculum
 
T beff
T beffT beff
T beff
 
Intrapleural stk
Intrapleural stkIntrapleural stk
Intrapleural stk
 
Guide to pleural_thickening
Guide to pleural_thickeningGuide to pleural_thickening
Guide to pleural_thickening
 
Naco guidelines for hiv aids management
Naco guidelines for hiv aids managementNaco guidelines for hiv aids management
Naco guidelines for hiv aids management
 
Traction bronchiectasis bronchiectasis notes
Traction bronchiectasis bronchiectasis notesTraction bronchiectasis bronchiectasis notes
Traction bronchiectasis bronchiectasis notes
 
Sgrq c%20 manual%202008
Sgrq c%20 manual%202008Sgrq c%20 manual%202008
Sgrq c%20 manual%202008
 
Pleural thickening 2009 janvol7issue1
Pleural thickening 2009 janvol7issue1Pleural thickening 2009 janvol7issue1
Pleural thickening 2009 janvol7issue1
 
Guide to pleural_thickening
Guide to pleural_thickeningGuide to pleural_thickening
Guide to pleural_thickening
 
Publication guidelines
Publication guidelinesPublication guidelines
Publication guidelines
 
Naco guidelines for hiv aids management
Naco guidelines for hiv aids managementNaco guidelines for hiv aids management
Naco guidelines for hiv aids management
 
Copd cipladoc
Copd cipladocCopd cipladoc
Copd cipladoc
 
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
Acquired a amyloidosis from injection drug use presenting with atraumatic spl...
 

Steroidsfleishman

  • 1. Adjunctive steroids for reducing residual pleural effusion in patients with TB CITATION Fleishman SI, Coetzee AM, Mindel S, Berjak J, Lichter AI. Antituberculous therapy combined with adrenal steroids in the treatment of pleural effusions: a controlled therapeutic trial. Lancet. 1960 Jan 23;1:199-201 RESEARCH QUESTION Compared to standard therapy, how effective is adjunctive steroid therapy for treating patients with pleural effusion of unknown cause? THE STUDY Controlled therapeutic trial. STUDY SETTING Central hospital within the mining area of Witwatersrand, Johannesburg. PARTICIPANTS Included: Mineworkers with pleural effusion of unknown cause, presumably all men. Excluded: Patients with Pulmonary Tuberculosis (TB), other TB, adenopathy, abdominal masses, vitamin deficiency, bilateral effusions. INTERVENTIONS 1. Treatment V: Ascorbic Acid 500mg IM daily for 14 days 2. Treatment P: Procaine Penicillin 300,000 units IM twice daily for 14 days 3. Treatment T: ATT (see below) 4. Treatment TS: ATT plus corticosteroids (see below) Regular ATT ATT Plus Description Streptomycin INH Prednisolone Dosage 1g IM 200mg orally 10mg orally, then 5 mg orally Frequency Daily 3 times/d 3 times daily, then 3 times daily for rest of 8 weeks Duration 8 wks 8 weeks for 2 days at higher dose, rest of 8 weeks at lower dose Co-interventions: 1. 3 tablets Vit B co daily 2. Bedrest OUTCOMES Primary: Reduction in the extent of pleural effusion Secondary: Are scurvy and pneumonia involved in the pathogenesis of pleurisy? RISK OF BIAS (Risk Scale: Low – Moderate – High) SELECTION BIAS: moderate to high Previously prepared sealed instructions of treatment. As each case was admitted to the trial, hospital clerical staff drew one so that the treatment was allocated at random. Table 1: Appears to be balanced for Initial weights and Initial ESR. However no other parameters (e.g. demographics) are reported on. The ESR appears to be low for TB for which you would normally expect readings of around 40+ mm/hr.
  • 2. PERFORMANCE BIAS: low (ie: What else happened that may have affected the result?) Patients not blinded - Not a problem since outcome is not affected by patient’s performance. Patients were confined to hospital – good compliance to therapy Period of bed rest varied according to “patient’s condition” – article did not clarify who made this judgement. Initial aspiration of 20 ml of pleural fluid may affect first four weeks’ score. DETECTION BIAS: low Pleural effusions were scored by a panel of 5 doctors who, according to the authors, were blinded to the patient's treatment. No indication that the laboratory staff was blinded. However, it appears as if the panel were aware of the treatment given at the beginning of the trial since on page 200, column 2 – "this result became known only at the completion of his course of treatment" almost indicating that they would have changed the treatment had they known? ATTRITION BIAS: No intention to treat analysis performed. P V ATT ATT + S Total Started 19 21 19 20 79 Completed 17 19 19 20 75 Assessed 16 18 19 20 73 STUDY FINDINGS Significant reduction in the extent of the effusion in TS at 4 weeks No significant reduction seen from 4 weeks to 8 weeks PRESENCE OF RESIDUAL FLUID (95% CI) Treatment Event Rate RRR ARR NNT 4 weeks TS E 11/20 = 0.55 35% 0.29 4 T C 16/19 = 0.84 (2%; 67%) (0.02; 0.57) (2 – 52) 8 weeks TS E 8/20 = 0.40 49% 0.39 3 T C 15/19 = 0.79 (14%; 85%) (0.11; 0.67) (1 – 9) ADVERSE EVENTS Four patients deteriorated: Treatment change from V, P to T, TS COMMENTS Adjunctive steroid therapy appears to be an effective treatment for reducing residual pleural fluid in patients with pleural effusion of unknown cause. Prepared by: MARK ENGEL E-mail: mark.engel@mrc.ac.za Date: 15 June 2004